论文部分内容阅读
目的:系统评价艾迪(AD)注射液联合化疗治疗结直肠癌(CRC)的疗效及安全性,为临床合理用药提供循证依据。方法:计算机检索中国生物医学期刊文献数据库、中国期刊全文数据库(CNKI)、PubMed、Medline、EMBase、GoogleScholar、Co-chrane图书馆,采用Mantel-Haenszel法对符合入选标准的文献进行Meta分析,计算优势比。结果:纳入8篇文献共计551例患者,其中AD组279例,对照组272例。与对照组比较,AD组化疗期间生存质量提高了28.10%[OR=0.39,95%C(I2.62,5.81),P2<0.00001],化疗期间白细胞毒性AD组降低23.80%[OR=0.41,95%CI(0.19,0.86),P2=0.02],感觉神经病变降低11.33%[OR=0.25,95%C(I0.15,0.43),P2<0.00001]。结论:AD治疗CRC可以提高患者生存质量,减少并发症的发生几率。经敏感性分析证实结论可靠。
OBJECTIVE: To systematically evaluate the efficacy and safety of AD and ADM in the treatment of colorectal cancer (CRC) and provide an evidence-based basis for clinical rational drug use. Methods: Meta-analysis was performed by using the Mantel-Haenszel method in the CNKI, PubMed, Medline, EMBase, Google Scholar and Co-chrane libraries. ratio. Results: A total of 551 patients were enrolled in 8 articles, including 279 cases in AD group and 272 cases in control group. Compared with the control group, the quality of life in AD group increased by 28.10% [OR = 0.39, 95% C (I2.62, 5.81), P2 <0.00001] 95% CI (0.19,0.86), P2 = 0.02], and sensory neuropathy decreased by 11.33% [OR = 0.25,95% C (I0.15,0.43), P2 <0.00001]. Conclusion: AD treatment of CRC can improve the quality of life of patients and reduce the incidence of complications. The sensitivity analysis confirmed the conclusion is reliable.